TIDMMYX TIDMMYXR
RNS Number : 5671Q
MyCelx Technologies Corporation
13 September 2017
13 September 2017
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). This inside
information is now considered to be in the public domain.
MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)
Half Year Results Statement
For the six months ended 30 June 2017
Improved performance as successful trial work opens new country
markets and renewed business development grows footprint and
momentum in Saudi Arabia
MYCELX Technologies Corporation ("MYCELX" or the "Company"), the
clean water technology company providing patented solutions for the
Oil and Gas market and commercial industrial markets worldwide, is
pleased to announce its interim unaudited results for the six
months ended 30 June 2017 for which highlights are set out
below.
Financial
-- 51% increase in Revenue YoY: $5.9 million (2016 H1: $3.9 million)
-- EBITDA of $0.3 million (2016 H1: negative $0.6 million)
-- Gross profit margin of 52.2% (2016 H1: 53.5%)
Operational
-- Contract awards reflect both the culmination of successful
pilot trial work in new regions and the reinvigoration of business
development efforts in the MENA region:
o Nigeria: Awarded first contract in the Nigerian Oil and Gas
market to provide an onshore water treatment solution to a leading
independent oil and gas producer
o Saudi Arabia: Awarded a contract for $1.1 million to rapidly
respond to the immediate water treatment needs of a new
SABIC-affiliate customer
o Saudi Arabia: Enhanced an existing system at a SABIC-affiliate
customer leading to increased operational and maintenance role and
greater recurring media sales
o Oman: Sale of Cooling Water treatment system after successful
trial in 2016
o Mauritania: Sale of oily water treatment system
Post Period
o Saudi Arabia: Extension of the rapid response unit deployment
to treat additional challenging waste water at new SABIC-affiliate
customer
o Canada: Successful trial for RE-GEN media with large producer
in polymer flood application
o Global: Finalist for World Oil's 2017 Awards for Best Enhanced
Oil Recovery Technology
Outlook
-- Leverage business relationships in the Middle East to
continue to grow downstream business in MENA
-- Adopt a managed growth approach to ensure that the momentum
is maintained while ensuring rigorous cost controls and cash
preservation
-- Continued focus on customer trials that lead to new equipment
sales and recurring media revenue
-- Work with Schlumberger's global sales and marketing platform
to bolster the successful trial work for RE-GEN that MYCELX has
undertaken with leading EOR producers
Commenting on these results, Connie Mixon, CEO, said:
"The Company has made good progress in H1 2017 with a series of
contract wins in new country markets while extending our footprint
in core markets. In the first half we delivered a positive EBITDA,
increasing revenue by $2 million despite the continued sluggish
industry environment.
It is pleasing that we are now beginning to see the benefits of
our 2016 pilot trial strategy come to fruition with our entry into
the Nigerian market where we have sold a complete treatment system
for an onshore facility.
In Saudi Arabia, the assignment of a Director of Business
Development has already resulted in new business, capitalising on
the strong foundations in that core market. Looking forward, our
focus will be on maintaining this renewed momentum and converting
the pipeline of opportunities to achieve critical mass in Saudi
Arabia and the GCC, while maintaining strict inventory and cost
controls.
In Canada, India and the Middle East, our collaborative study
undertaken with SNF Floerger has led to further interest and trials
for leading Enhanced Oil Recovery (EOR) producers. These trials,
together with our strategic partnership with Schlumberger, are
helping to increase industry recognition of the step change
improvement that our RE-GEN product delivers. This is further
demonstrated by the fact that MYCELX RE-GEN was nominated as a
finalist for Best EOR Technology in the 2017 World Oil Awards, and
we have been asked to speak at the upcoming Produced Water Society
Conference in the Middle East.
MYCELX is a technology company that continues to expand its
exceptional water treatment expertise. MYCELX's growing knowledge
base supports the innovation and commercialisation of next
generation technology to meet our customers' current and future
needs. We are more reliable and cost effective than outdated
conventional methods. The oil and gas and petrochemical industries
are integrating MYCELX(R) technology into critical, real-time
production and processes, where increased uptime performance goes
straight to the bottom line. Our technology will deliver
sustainable water treatment for years to come."
For further information please contact:
MYCELX Technologies Corporation
Connie Mixon, CEO Tel: +1 888 306 6843
Kim Slayton, CFO
Cantor Fitzgerald Europe - NOMAD and Broker
Andrew Craig Tel: +44 20 7894 7000
Richard Salmond
Celicourt Communications
Mark Antelme Tel: +44 20 7520 9266
Jimmy Lea
Chairman's and Chief Executive Officer's Statement
Introduction:
Market conditions during the first half of 2017 continued to be
challenging for the oil and gas industry as uncertainty remains
around the strength of the oil price recovery and the petrochemical
industry remains in tight cost control mode. The oil and gas
service sector experienced more consolidation as a result of two
years of curtailed activity and delayed investment by producers. In
the face of this tenuous and extremely cost-conscious market,
MYCELX is pleased to report that the Company has delivered a
positive EBITDA for H1 2017, increasing revenue by $2 million,
compared to H1 2016, despite the continued sluggish industry
environment. We have achieved this improved performance from a
combination of renewed business development and the strict cost
control measures that have become engrained in the Company's
general approach. It is this managed growth approach that will
allow the Company to successfully navigate an industry well known
for its boom and bust cycles.
Our H1 results were underpinned by winning two large contracts,
one in a new country and the other extending our footprint in our
leading market, and we are pleased to note a resurgence in momentum
in the Company's efforts across all operational fronts. Opening up
the Nigerian market offers a host of opportunities where our
solutions will both improve water treatment but also enhance
production. In Saudi Arabia, our new Director of Business
Development is spearheading efforts to leverage our strategic
assets to chase down opportunities. Successful trial collaboration
work on RE-GEN with SNF Floerger has led to in-field trials where
RE-GEN has demonstrated its superior capability to leading EOR
producers across the globe. These trials together with our
strategic partnership with Schlumberger are helping to increase
industry recognition of the step change improvement that our RE-GEN
product delivers. This is further demonstrated by the fact that
RE-GEN has been nominated as a finalist for Best EOR Technology in
the 2017 World Oil Awards.
Operational Review
Middle East and North Africa
The first half of 2017 has seen a resurgence in momentum in the
MENA region for MYCELX, especially within Saudi Arabia. Recognizing
the immense opportunities in the region, in early 2017 the Company
added a Director of Business Development for MENA and Asia who
resides in and oversees the regional business initiative from Al
Jubail Industrial City, where the Company has had continuous
business operations since 2010. This addition of this position
demonstrates the enthusiasm the Company has for the future of
MYCELX technology in the region. This appointment has acted as the
necessary catalyst to consolidate our position and restore momentum
in this core market. By leveraging our strong track record, proven
cost saving solutions and the ability to deploy quickly, due to our
in-country rental equipment fleet, we have been able to chase down
and seize new opportunities. This renewed and proactive engagement
with existing customers is leading to new opportunities, with
customers considering either expansions of existing MYCELX systems
or deployment of our technology for further applications at their
sites. In this manner, a new customer win for the Company is merely
the beginning of a relationship that can lead to several contract
wins.
The Company has ongoing activity in the downstream and upstream
markets in the GCC. In the downstream petrochemical sector, the
Company is treating quench water for reuse in the petrochemical
process, managing challenging oily water onsite by deploying
equipment from the rental fleet and is engaged in intermittent
plant turnaround operations. The Company's downstream strategy
continues to target delivering reliable production uptime in the
quench water loop which creates cost benefits that directly enhance
the bottom line. This niche application and unique capability is
attributable to the small footprint and highly efficient technology
MYCELX provides, where space is limited and performance is key to
ongoing operations and consistent production. In the upstream
sector, the target market is produced water treatment during EOR
production. The aging fields in the Middle East are deploying
advanced EOR methods to extract more oil from their reservoirs.
These methods require more advanced water treatment and MYCELX has
been successfully trialed in the Middle East and other locations to
treat EOR produced water. The Company views the EOR market as one
of the largest water plays for years to come.
One of the key reasons that our Saudi Arabian customers choose
MYCELX solutions is that we are always ready and prepared to solve
their problems. We have a dedicated 24/7 hour service office in
Jubail, and our rental equipment fleet has meant that we can
quickly deploy solutions to their sites. It was this rapid response
customer service that led to our recent new SABIC customer win.
MYCELX was awarded a $1.1 million contract to rapidly deploy its
in-country rental fleet equipment to treat an immediate waste water
situation. Our solution was so successful and cost effective that
the customer requested that we extend our deployment of the unit to
treat other waste water sources. Recognition that our solutions
offer superior treatment performance and significant cost benefits
by removing the need for costly haulage off site is growing within
Saudi Arabia and has resulted in further opportunities which the
Company is currently pursuing.
Adding to the large scale wins, the Company was awarded two
small-scale contracts to deliver oily water treatment systems in
Oman and Mauritania. Each of these installations will produce
recurring revenue adding to the ongoing legacy media sales.
Nigeria
In an exciting contract award for the Company, MYCELX opened the
Nigerian market with the sale of an onshore water treatment
solution to a leading independent oil and gas producer focused on
the development of its reserves in the Niger Delta. MYCELX's
complete water system will be deployed to solve cost effectively
the current and future water challenges as the operator progresses
to use water injection and enhanced oil recovery techniques to
further increase production and reserves. The sale of this complete
system is important not only because it opens up an exciting new
geographical frontier for MYCELX and supports our internal 2017
growth projections, but it also marks the first contract award from
our concerted efforts in 2016 of working directly with clients to
explore how our technology can best support their goals through
many months of trials and collaboration. The on-going sale of
filter media will further add to MYCELX's recurring revenue base.
The Company will continue to market in Nigeria where it sees vast
opportunity for its technology. MYCELX not only supports the goals
of producers who are striving to reduce the environmental impact of
industry, it fits their plans to ramp up their production into the
future using enhanced oil recovery techniques which plays to
MYCELX's experience and strength.
North America
MYCELX operates in both the offshore and onshore markets in the
United States. Due to our technology's small footprint, we have
been retrofitted or scoped into the design of Gulf of Mexico rigs
such as Jack St Malo. During H1, the Company has seen an
improvement in the demand for media from such installations. The US
onshore market is ramping up activity with certain producers
aggressively increasing production, which will require more
effective produced water recycling. Our innovative technology
enables producers to recycle produced water while mitigating the
need for fresh water during operations and is in increasing demand.
MYCELX is working with its strategic partner Schlumberger on
pursuing the US onshore market with an advanced water recycle
system that includes effective complementary technologies. MYCELX
has sold and supported systems for onshore water treatment in the
past therefore we are enthusiastic the combined system will bring
better performance to produced water recycle applications.
EOR - Canada & India
MYCELX's efforts in the EOR market are focused on growing
industry recognition of our RE-GEN media's superior results when
treating EOR produced water. In 2016, MYCELX collaborated with SNF
Floerger on a white paper that demonstrated in the lab that RE-GEN
was able to effectively treat polymer laden water, and actually
preserves the valuable polymer thereby improving the overall
economics of this effective EOR technique. As a result of that
collaborative paper, MYCELX was invited to conduct onsite trials
with some of the leading polymer flood producers in the world.
Post the period under review, MYCELX conducted a successful
RE-GEN media trial at a polymer flood field with a major Canadian
producer. With the improved oil price, producers are once again
looking to implement technology that provides cost benefits and
performance beyond what they have experienced with conventional
technologies. The capabilities of the RE-GEN media in polymer flood
applications is best demonstrated with pilot trials so the end user
sees first-hand the remarkable performance and ease of operation.
The primary goal of the trials is to highlight the differentiators
of RE-GEN and conventional equipment that is onsite. This approach
has had the greatest impact on end users. MYCELX has been active in
Alberta for five years and, with the oil price recovery, looks
forward to pushing forward in a market where increased EOR activity
looks set to continue well into the future.
During H1 the Company also continued trialing in India where
production goals for future field expansion lie in further
implementation of enhanced oil recovery techniques. These projects
are extremely complex and have far-reaching implications for the
producers. As such, the timelines are long. Nonetheless, lessons
learned and the vast experience MYCELX has gained through prolonged
onsite EOR trials is unparalleled and invaluable to future success
in India and elsewhere globally. MYCELX RE-GEN media is capable of
treating water during enhanced oil recovery operations and polymer
flood in particular. Recognizing conventional water treatment in
the EOR market has struggled to match the production technique
advances, MYCELX will continue to trial our technology to showcase
the efficacy of the RE-GEN media in this lucrative global
application and leverage the knowledge base the Company has
amassed.
Financial
Total revenue increased by 51.3% to $5.9 million for the first
half of 2017, compared to $3.9 million in the first half of 2016.
Revenue from equipment sales and leases increased by 130.8% to $3.0
million in the first half of 2017 (2016 H1: $1.3 million), while
revenue from consumable filtration media and service increased
11.5% to $2.9 million (2016 H1: $2.6 million). Gross profit
increased by 47.6% to $3.1 million in the first half of 2017,
compared to $2.1 million in the first half of 2016. Gross profit
margin decreased in the first half of 2017 to 52.2% (2016 H1:
53.5%) due to a larger portion of total revenue coming from
equipment sales.
Total operating expenses for the first half of 2017 were $3.4
million which is consistent with the first half of 2016. The
largest component of operating expenses was selling, general and
administrative ("SG&A") expenses which includes $1.8 million of
staff costs.
EBITDA was $300,000 for the first half of 2017, compared to
negative $600,000 for the first half of 2016. EBITDA is net income
before interest expense, provision for income taxes, depreciation
and amortisation of fixed and intangible assets including
depreciation of leased equipment which is included in cost of goods
sold. The Company uses EBITDA as the profitability measure for
making decisions regarding allocating resources and assessing
performance.
The Company recorded a loss before tax of $350,000 in the first
half of 2017 compared to a loss before tax of $1.4 million in the
first half of 2016. Basic loss per share was 3 cents for the first
half of 2017, compared to basic loss per share of 8 cents for the
first half of 2016.
Cash preservation continues to be an imperative for the Company
and MYCELX ended the period with $4.7 million of cash and cash
equivalents, including restricted cash. The Company experienced an
operating cash outflow of approximately $900,000 in the first half
of 2017, compared to an operating cash inflow of $200,000 for the
first half of 2016. The outflow was due to the timing of customer
payments that were subsequently received in early July.
In keeping with the goals and parameters set in 2015 the Company
will continue to be a prudent steward of its cash with monitoring
in place to ensure specific measures are taken in the event of a
revenue shortfall or contract delay during the year and any
additional equipment purchased will be supported by a sales
contract. The ability to convert business development opportunities
into cash generation while maintaining effective expense control
demonstrates the discipline and focus of the entire Company.
Outlook
As the market recovers and resets the Board of Directors and the
Company are well aware of the challenges the Company faces. MYCELX
believes that market conditions could improve in H2 but is
maintaining a cautious outlook for its business for the remainder
of the year. We plan to enhance our prospects for new contract
wins, preserve existing revenue streams and maintain our cost
control program. We continue to believe long-term success and
building a global brand will be achieved by engaging in large scale
projects as well as smaller scale, fast-to-market opportunities of
which both have been achieved in H1. We continue to progress large,
complex projects by undertaking paid trials to refine the water
treatment solution to meet customers' specific requirements. During
H1 and post period we closed three small scale projects which was a
goal of the Company mentioned last year. These projects will bridge
the gap of lengthy project timelines and will be additive to annual
recurring revenue for years to come.
Our immediate growth strategy remains focused on geographic
regions of the Middle East, North America and the recent addition
of Nigeria. While tenuous, the improved price stability in the Oil
and Gas market as well as industry producers adjusting to the new
oil price range has resulted in opportunities with operators keen
to seek out advanced technology. MYCELX offers better performance,
cost benefits through increased production uptime and relief from
conventional technology that struggles to keep pace with new
extraction techniques and process improvements. Each of our
targeted geographical markets is water stressed therefore each has
need and significant bottom-line incentive to adopt technology that
offers better uptime performance, requires less water during
operations and supports major environmental goals in the
region.
We continue to pursue strategic partnerships to leverage sales
and marketing platforms that value differentiated technology. It is
clear that the Oil and Gas industry wants and needs technology that
can effectively perform and deliver strong cost benefits to
operations. The ongoing adoption of MYCELX technology as
demonstrated by more contract wins is further confirmation that our
technology has its role in achieving sustainable water treatment
for years to come. Our strategic partnership with Schlumberger has
supported these efforts to broadcast our capabilities to a wider
global audience. Our goal is to be the industry leader by providing
the technology and expertise necessary to stay ahead of the
production and process advancements of the Oil and Gas industry and
paving the way for the future of water treatment.
MYCELX management takes a focused approach and constantly
refines its evaluation process for project pipeline opportunities
to ensure all resources expended are cost efficient and in
alignment with project expectations. We continue to take a risked
approach to our revenue outlook and taken together with our cost
cutting initiatives the Company is on track to achieve our cash
goals for the full year 2017.
At its core, the Company is a technology company with
exceptional water expertise gained through onsite, real-time water
treatment experience. The library of knowledge the Company has
amassed in its specific applications with MYCELX technology is
unparalleled in industry. The Company will continue to use this
knowledge to innovate and pave the way for next generation
technology to meet our customers' current and future needs more
reliably and cost effectively than outdated conventional methods.
The endorsement and support of Schlumberger in upstream along with
the footprint we have established with leading operators around the
world positions MYCELX well to achieve its ultimate goal of
becoming the new industry standard for water treatment.
Tim Eggar Connie Mixon
Chairman Chief Executive Officer
13 September 2017
MYCELX TECHNOLOGIES CORPORATION
Statements of Operations
(USD, in thousands, except share
data)
Six Months Six Months Year
Ended Ended Ended
30 June 30 June 31 December
2017 2016 2016
(unaudited) (unaudited)
----------------- ---------------- -------------------------
Revenue 5,877 3,945 7,923
Cost of goods sold 2,808 1,834 3,820
Gross profit 3,069 2,111 4,103
----------------- ---------------- -------------------------
Operating expenses:
Selling, general and administrative 3,160 3,180 6,588
Depreciation and amortisation 216 268 499
----------------- ---------------- -------------------------
Total operating expenses 3,376 3,448 7,087
----------------- ---------------- -------------------------
Operating loss (307) (1,337) (2,984)
Other expense
Loss on disposal of equipment - - (2)
Interest expense (45) (47) (94)
----------------- ---------------- -------------------------
Loss before income taxes (352) (1,384) (3,080)
Provision for income taxes (152) (116) (199)
----------------- ---------------- -------------------------
Net loss (504) (1,500) (3,279)
================= ================ =========================
Loss per share-basic (0.03) (0.08) (0.17)
================= ================ =========================
Loss per share-diluted (0.03) (0.08) (0.17)
================= ================ =========================
Shares used to compute basic loss
per share 18,770,117 18,770,117 18,770,117
================= ================ =================
Shares used to compute diluted
loss per share 18,770,117 18,770,117 18,770,117
================= ================ =================
The accompanying notes are an integral part of the financial
statements.
MYCELX TECHNOLOGIES CORPORATION
Balance Sheets
(USD, in thousands, except share
data)
As of As of As of
30 June 30 June 31 December
2017 2016 2016
(unaudited) (unaudited)
------------ ------------------ ------------
ASSETS
Current Assets
Cash and cash equivalents 4,170 5,246 5,139
Restricted cash 500 500 500
Accounts receivable - net 3,866 2,502 1,941
Unbilled accounts receivable 680 57 94
Inventory 3,070 3,269 3,190
Prepaid expenses 348 205 126
Other assets 33 76 36
---------------- ------------------ ------------
Total Current Assets 12,667 11,855 11,026
Property and equipment -
net 9,299 11,213 10,487
Intangible assets - net 844 811 852
Total Assets 22,810 23,879 22,365
================ ================== ============
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current Liabilities
Accounts payable 891 531 657
Payroll and accrued expenses 487 629 425
Deferred revenue 661 - -
Note payable - current 87 83 85
Other current liabilities 437 119 436
---------------- ------------------ ------------
Total Current Liabilities 2,563 1,362 1,603
Note payable - long-term 1,877 1,964 1,921
---------------- ------------------ ------------
Total Liabilities 4,440 3,326 3,524
---------------- ------------------ ------------
Stockholders' Equity
Common stock, $0.025 par value,
100,000,000 shares authorised,
18,770,117 shares issued and
outstanding at 30 June 2017
and 2016, and 31 December 2016.
469 469 469
Additional paid-in capital 40,358 40,258 40,325
Accumulated deficit (22,457) (20,174) (21,953)
---------------- ------------------ ------------
Total Stockholders' Equity 18,370 20,553 18,841
---------------- ------------------ ------------
Total Liabilities and Stockholders'
Equity 22,810 23,879 22,365
================ ================== ============
The accompanying notes are an integral part of the financial
statements.
MYCELX TECHNOLOGIES
CORPORATION
Statements of Stockholders'
Equity
(USD, in thousands)
Additional
Common Paid-in Accumulated
Stock
Capital Deficit Total
Shares $ $ $ $
------- ---- ----------- ------------ --------
Balances at 31 December
2015 18,770 469 40,202 (18,674) 21,997
Stock-based compensation
expense - - 56 - 56
Net loss for the period - - - (1,500) (1,500)
------- ---- ----------- ------------ --------
Balances at 30 June
2016 (unaudited) 18,770 469 40,258 (20,174) 20,553
Stock-based compensation
expense - - 67 - 67
Net loss for the period - - - (1,779) (1,779)
------- ---- ----------- ------------ --------
Balances at 31 December
2016 18,770 469 40,325 (21,953) 18,841
Stock-based compensation
expense - - 33 - 33
Net loss for the period - - - (504) (504)
------- ---- ----------- ------------ --------
Balances at 30 June
2017 (unaudited) 18,770 469 40,358 (22,457) 18,370
======= ==== =========== ============ ========
The accompanying notes are an integral part of the financial
statements.
MYCELX TECHNOLOGIES CORPORATION
Statements of Cash Flows
(USD, in thousands)
Six Months Six Months Year
Ended Ended Ended
30 June 30 June 31 December
2017 2016 2016
(unaudited) (unaudited)
------------- ------------- -------------
Cash flow from operating activities
Net loss (504) (1,500) (3,279)
Adjustments to reconcile net
loss to net cash (used in)
provided by operating activities:
Depreciation and amortisation 617 728 1,384
Loss from disposition of
equipment - - 2
Stock compensation 33 56 123
Change in operating assets
and liabilities:
Accounts receivable (1,925) 353 914
Unbilled accounts receivable (586) (37) (74)
Inventory 716 521 591
Prepaid expenses (222) (1) 78
Other assets 3 33 73
Accounts payable 234 46 172
Payroll and accrued expenses 62 52 (158)
Deferred revenue 661 (42) (42)
Other current liabilities 1 4 321
Net cash (used in) provided
by operating activities (910) 213 105
------------- ------------- -------------
Cash flow from investing activities
Payments for purchases of
property and equipment (2) (207) (109)
Proceeds from sale of property
and equipment - - 7
Payments for purchases of
intangible assets (15) (22) (85)
------------- ------------- -------------
Net cash used in investing
activities (17) (229) (187)
------------- ------------- -------------
Cash flows from financing
activities
Payments on notes payable (42) (34) (75)
Net cash used in financing
activities (42) (34) (75)
------------- ------------- -------------
Net decrease in cash and cash
equivalents (969) (50) (157)
------------- ------------- -------------
Cash and cash equivalents,
beginning of period 5,139 5,296 5,296
Cash and cash equivalents,
end of period 4,170 5,246 5,139
============= ============= =============
Supplemental disclosures of cash
flow information:
Cash payments for interest 45 39 86
Cash and non-cash payments for
income taxes 159 164 216
Non-cash movements of inventory
and fixed assets 596 (102) (9)
Management considered the effect of exchange rate changes
on cash and cash equivalents held or due in foreign
currency and deemed it immaterial to the statement of
cash flows.
The accompanying notes are an integral part of the financial
statements.
NOTES TO THE FINANCIAL STATEMENTS
1. Nature of business and basis of presentation
Basis of presentation - These interim financial statements have
been prepared using recognition and measurement principles of
Generally Accepted Accounting Principles in the United States of
America ("U.S. GAAP").
The interim financial statements for the six months ended 30
June 2017 and 2016 have not been audited.
Nature of business - MYCELX Technologies Corporation ("MYCELX"
or the "Company") was incorporated in the State of Georgia on 24
March 1994. The Company is headquartered in Duluth, Georgia with
operations in Houston, Texas, Saudi Arabia, India and the United
Kingdom. The Company provides clean water technology equipment and
related services to the oil and gas, power, marine and heavy
manufacturing sectors and the majority of its revenue is derived
from the Middle East and United States.
2. Summary of significant accounting policies
Use of estimates - The preparation of financial statements in
conformity with U.S. GAAP requires management to make estimates and
assumptions that affect certain reported amounts and disclosures.
The primary estimates and assumptions made relate to depreciation
and amortisation, share-based compensation and deferred taxes.
Actual results could differ from these estimates and the
differences may be material to the financial statements.
Cash and cash equivalents - Cash and cash equivalents consist of
short-term, highly liquid investments which are readily convertible
into cash within ninety (90) days of purchase. At 30 June 2017, all
of the Company's cash and cash equivalent balances were held in non
interest-bearing transaction accounts. The Company maintains its
cash in bank deposit accounts which, at times, may exceed federally
insured limits. At 30 June 2017 and 2016, and 31 December 2016,
cash in non-U.S. institutions was $98,000, $140,000 and $140,000,
respectively. The Company has not experienced any losses in such
accounts.
Restricted cash - The Company classifies as restricted cash all
cash whose use is limited by contractual provisions. At 30 June
2017 and 2016, and 31 December 2016, restricted cash included
$500,000 cash on deposit in a money market account as required by a
lender (see Note 9).
Trade accounts receivable - Trade accounts receivable are stated
at the amount management expects to collect from outstanding
balances. The Company provides credit in the normal course of
business to its customers and performs ongoing credit evaluations
of those customers and maintains allowances for doubtful accounts,
as necessary. Accounts are considered past due based on the
contractual terms of the transaction. Credit losses, when realised,
have been within the range of the Company's expectations and,
historically, have not been significant. The allowance for doubtful
accounts at 30 June 2017 and 2016, and 31 December 2016 was
$208,000, $nil and $143,000, respectively.
Inventories - Inventories consist primarily of raw materials and
filter media finished goods as well as equipment to house the
filter media and are stated at the lower of cost or net realisable
value. Equipment that is in the process of being constructed for
sale or lease to customers is also included in inventory
(work-in-progress). The Company applies the FIFO method (first in;
first out) to account for inventory. Manufacturing work-in-progress
and finished products inventory include all direct costs, such as
labor and material, and those indirect costs which are related to
production, such as indirect labor, rents, supplies, repairs and
depreciation costs. A valuation reserve is recorded for slow moving
or obsolete inventory items to reduce the cost of inventory to its
net realisable value.
Prepaid expenses and other current assets - Prepaid expenses and
other current assets include non-trade receivables that are
collectible in less than twelve months, security deposits on leased
space and various prepaid amounts that will be charged to expenses
within twelve months. Non-trade receivables that are collectible in
twelve months or more are included in long-term assets.
Property and equipment - All property and equipment are valued
at cost. Depreciation is computed using the straight-line method
for financial reporting over the following useful lives:
Buildings 39 years
Leasehold improvements 1-5 years
Office equipment 3-10 years
Manufacturing equipment 5-15 years
Research and development equipment 5-10 years
Purchased software 1-5 years
Equipment leased to customers 3-10 years
Expenditures for major renewals and betterments that extend the
useful lives of property and equipment are capitalised.
Expenditures for maintenance and repairs are charged to expense as
incurred. Depreciation expense includes depreciation on equipment
leased to customers and is included in cost of goods sold.
Intangible assets - Intangible assets consist of the costs
incurred to purchase patent rights and legal and registration costs
incurred to internally develop patents. Intangible assets are
reported net of accumulated amortisation. Patents are amortised
using the straight-line method over a period based on their
contractual lives which approximates their estimated useful
lives.
Revenue recognition - The Company's revenue consists of media
product and equipment sales. Revenues from media sales are
recognised, net of sales allowances and sales tax, when products
are shipped and risk of loss has transferred to customers,
collection is probable, persuasive evidence of an arrangement
exists, and the sales price is fixed or determinable. The Company
offers customers the option to lease or purchase their equipment.
Lease agreements range from one to twenty-four months in length and
are renewed at the end of each agreement, if necessary. The lease
agreements meet the criteria for classification as operating
leases; accordingly, revenue on lease agreements is recognised as
income over the lease term. Revenues on long-term contracts related
to construction of equipment are recognised, net of sales tax, on
the percentage-of-completion basis using costs incurred compared to
total estimated costs. Costs are recognised and considered for
percentage-of-completion as they are incurred in the manufacture of
the equipment. Therefore, revenues may not be related to the
progress billings to customers. Revenues are based on estimates,
and the uncertainty inherent in estimates initially is reduced
progressively as work on the contract nears completion. Revenues on
sales in which equipment is pre-fabricated and stocked in inventory
are recognised, net of sales tax, upon shipment of the equipment to
the customer.
Contract costs include all direct labor and benefits, materials
unique to or installed to the project, subcontractor costs, as well
as costs relative to contract performance such as travel to a
customer site and shipping charges. Provision for estimated losses
on uncompleted contracts is recorded in the period in which such
losses are probable and estimable. No such provisions have been
recognised as of 30 June 2017 and 2016, and 31 December 2016.
Changes in job performance, job conditions, and estimated
profitability may result in revisions to costs and income, which
are recognised in the period in which the revisions are determined.
Actual results could vary from estimates used in the financial
statements.
Unbilled accounts receivable represents revenues recognised in
excess of amounts billed. Deferred revenue represents billings in
excess of revenues recognised. Contract retentions are recorded as
a component of accounts receivable.
Impairment of long-lived assets - Long-lived assets to be held
and used, including property and equipment and intangible assets
with definite useful lives, are assessed for impairment whenever
events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. If the total of the
expected undiscounted future cash flows is less than the carrying
amount of the asset, a loss, if any, is recognised for the
difference between the fair value and carrying value of the assets.
Impairment analyses, when performed, are based on the Company's
business and technology strategy, management's views of growth
rates for the Company's business, anticipated future economic and
regulatory conditions, and expected technological availability. For
purposes of recognition and measurement, the Company groups its
long-lived assets at the lowest level for which there are
identifiable cash flows, which are largely independent of the cash
flows of other assets and liabilities. No impairment charges were
recorded in the six months ended 30 June 2017 and 2016, and the
year ended 31 December 2016.
Shipping and handling costs - Consistent with Financial
Accounting Standards Board ("FASB") Accounting Standards
Codification ("ASC") 605-45-50 Shipping and Handling Fees and
Costs, the Company classifies shipping and handling amounts billed
to customers as revenue, and shipping and handling costs as a
component of costs of goods sold.
Research and development costs - Research and development costs
are expensed as incurred. There was no Research and development
expense for the six months ended 30 June 2017 and 2016, and the
year ended 31 December 2016.
Advertising costs - The Company expenses advertising costs as
incurred. Advertising expense for the six months ended 30 June 2017
and 2016, and the year ended 31 December 2016 was approximately
$nil, $nil and $4,000, respectively, and is recorded in selling,
general and administrative expenses.
Rent expense - The Company records rent expense on a
straight-line basis for operating lease agreements that contain
escalating rent clauses. The deferred rent liability included in
other current liabilities in the accompanying balance sheet
represents the cumulative difference between rent expense
recognised on the straight-line basis and the actual rent paid.
Income taxes - The provision for income taxes for interim and
annual periods is determined using the asset and liability method,
under which deferred tax assets and liabilities are calculated
based on the temporary differences between the financial statement
carrying amounts and income tax bases of assets and liabilities
using currently enacted tax rates. The deferred tax assets are
recorded net of a valuation allowance when, based on the weight of
available evidence, it is more likely than not that some portion or
all of the recorded deferred tax assets will not be realised in
future periods. Decreases to the valuation allowance are recorded
as reductions to the provision for income taxes and increases to
the valuation allowance result in additional provision for income
taxes. The realisation of the deferred tax assets, net of a
valuation allowance, is primarily dependent on the ability to
generate taxable income. A change in the Company's estimate of
future taxable income may require an addition or reduction to the
valuation allowance.
The benefit from an uncertain income tax position is not
recognised if it has less than a 50 percent likelihood of being
sustained upon audit by the relevant authority. For positions that
are more than 50 percent likely to be sustained, the benefit is
recognised at the largest amount that is more-likely-than-not to be
sustained. An uncertain income tax position is not recognised if it
has less than a 50 percent likelihood of being sustained. Where a
net operating loss carried forward, a similar tax loss or a tax
credit carry forward exists, an unrecognised tax benefit is
presented as a reduction to a deferred tax asset. Otherwise, the
Company classifies its obligations for uncertain tax positions as
other non-current liabilities unless expected to be paid within one
year. Liabilities expected to be paid within one year are included
in the accrued expenses account.
The Company recognises interest accrued related to tax in
interest expense and penalties in selling, general and
administrative expenses. During the six months ending 30 June 2017
and 2016, and the year ended 31 December 2016 the Company
recognised no interest or penalties.
Earnings per share - Basic earnings per share is computed using
the weighted average number of common shares outstanding during the
period. Diluted earnings per share is computed using the weighted
average number of common and potentially dilutive shares
outstanding during the period. Potentially dilutive shares consist
of the incremental common shares issuable upon conversion of the
exercise of common stock options. Potentially dilutive shares are
excluded from the computation if their effect is antidilutive.
Total common stock equivalents that were excluded from computing
diluted net loss per share were approximately 1,043,441, 1,106,645,
and 1,125,640 for the six months ended 30 June 2017 and 2016, and
the year ended 31 December 2016, respectively.
Fair value of financial instruments - The Company uses the
framework in ASC 820, Fair Value Measurements and Disclosures, to
determine the fair value of its financial assets. ASC 820
establishes a fair value hierarchy that prioritises the inputs to
valuation techniques used to measure fair value and expands
financial statement disclosures about fair value measurements.
The hierarchy established by ASC 820 gives the highest priority
to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to
unobservable inputs (Level 3 measurements).
The three levels of the fair value hierarchy under ASC 820 are
described below:
-- Level 1: Unadjusted quoted prices in active markets for
identical assets or liabilities that the Company has the ability to
access at the measurement date.
-- Level 2: Inputs other than quoted prices included within
Level 1 that are observable for the asset or liability, either
directly or indirectly.
-- Level 3: Unobservable inputs for the asset or liability.
There were no significant transfers into or out of each level of
the fair value hierarchy for assets measured at the fair value for
the six months ended 30 June 2017 and 2016, and the year ended 31
December 2016.
All transfers are recognised by the Company at the end of each
reporting period.
Transfers between Levels 1 and 2 generally relate to whether a
market becomes active or inactive. Transfers between Levels 2 and 3
generally relate to whether significant relevant observable inputs
are available for the fair value measurement in their entirety.
The Company's financial instruments as of 30 June 2017 and 2016,
and 31 December 2016 include cash and cash equivalents, accounts
receivable, accounts payable, the line of credit, and the note
payable. The carrying values of cash and cash equivalents, accounts
receivable, accounts payable, and the line of credit approximate
fair value due to the short-term nature of those assets and
liabilities. The Company believes it is impractical to disclose the
fair value of the note payable as it is an illiquid financial
instrument.
Foreign currency transactions - From time to time the Company
transacts business in foreign currencies (currencies other than the
United States Dollar). These transactions are recorded at the rates
of exchange prevailing on the dates of the transactions. Foreign
currency transaction gains or losses are included in selling,
general and administrative expenses.
Share-based compensation - The Company issues equity-settled
share-based awards to certain employees, which are measured at fair
value at the date of grant. The fair value determined at the grant
date is expensed, based on the Company's estimate of shares that
will eventually vest, on a straight-line basis over the vesting
period. Fair value for the share awards representing equity
interests identical to those associated with shares traded in the
open market is determined using the market price at the date of
grant. Fair value is measured by use of the Black Scholes valuation
model (see Note 10).
Recently issued accounting standards - In May 2014, the FASB
issued Accounting Standards Update ("ASU") 2014-09, "Revenue from
Contracts with Customers (Topic 606)", as subsequently amended,
which is the new comprehensive revenue recognition standard that
will supersede all existing revenue recognition guidance under U.S.
GAAP. The standards' core principle is that a company will
recognise revenue when it transfers promised goods or services to a
customer in an amount that reflects the consideration to which the
company expects to be entitled in exchange for those goods or
services. In August 2015, the FASB issued ASU 2015-14, which defers
the effective date of ASU 2014-09 for all entities by one year.
Accordingly, the standard is effective for annual periods beginning
after 15 December 2018, and interim periods therein, with early
adoption permitted. Entities will have the option of using either a
full retrospective approach or a modified approach to adopt the
guidance. The Company is currently evaluating the impact of
adopting this guidance but does not expect it to have a material
impact on the Company's financial statements.
In February 2016, the FASB issued ASU 2016-02, "Leases (Topic
842)", which requires lessees to recognise on the balance sheet the
assets and liabilities for the rights and obligations created by
the leases with lease terms of more than twelve months. The
recognition, measurement, and presentation of expenses and cash
flows arising from a lease by a lessee will continue to primarily
depend on its classification as a finance or operating lease.
However, unlike current U.S. GAAP, which requires only capital
leases be recognised on the balance sheet, the new standard will
require both types of leases to be recognised on the balance sheet.
The new standard also requires disclosures about the amount,
timing, and uncertainty of cash flows arising from leases. These
disclosures include qualitative and quantitative requirements,
providing additional information about the amounts recorded in the
financial statements. The new standard is effective for fiscal
years beginning after 15 December 2019, and for interim and annual
periods thereafter, with early application permitted. The Company
is currently evaluating the impact of adopting this guidance but
does not expect it to have a material impact on the Company's
financial statements.
In March 2016, the FASB issued ASU 2016-09, "Stock Compensation
(Topic 718): Improvements to Employee Share-Based Payment
Accounting", which amends several aspects of the accounting for
employee share-based payment transactions including the accounting
for income taxes, forfeitures and statutory tax withholding
requirements, as well as classification in the statement of cash
flows. The standard is effective for annual reporting periods
beginning after 15 December 2017, and interim periods within annual
periods beginning after 15 December 2018, with early application
permitted. The Company is currently evaluating the impact of
adopting this guidance but does not expect it to have a material
impact on the Company's financial statements.
3. Accounts receivable
Accounts receivable and their respective allowance amounts at 30
June 2017 and 2016, and 31 December 2016:
30 June 30 June 31 December
2017 2016 2016
US$000 US$000 US$000
Accounts receivable 4,074 2,502 2,084
Less: allowance
for doubtful accounts (208) - (143)
---------- ---------- --------------
Total receivable
- net 3,866 2,502 1,941
========== ========== ==============
4. Inventories
Inventories consist of the following at 30 June 2017 and 2016,
and 31 December 2016:
30 June 30 June 31 December
2017 2016 2016
US$000 US$000 US$000
Raw materials 735 797 756
Work-in-progress 4 1 -
Finished goods 2,331 2,471 2,434
---------- ---------- --------------
Total inventory
- net 3,070 3,269 3,190
========== ========== ==============
5. Property and equipment
Property and equipment consists of the following at 30 June 2017
and 2016, and 31 December 2016:
30 June 30 June 31 December
2017 2016 2016
US$000 US$000 US$000
Land 709 709 709
Building 2,724 2,724 2,724
Leasehold improvements 341 340 341
Office equipment 718 745 723
Manufacturing equipment 854 917 854
Research and development
equipment 514 514 514
Purchased software 222 222 222
Equipment leased to
customers 8,464 8,884 8,837
Construction in progress 443 826 730
---------- ---------- --------------
14,989 15,881 15,654
Less: accumulated
depreciation (5,690) (4,668) (5,167)
---------- ---------- --------------
Property and equipment
- net 9,299 11,213 10,487
========== ========== ==============
During the six months ended 30 June 2017 and 2016, and the year
ended 31 December 2016, the Company removed property, plant and
equipment and the associated accumulated depreciation of
approximately $71,000, $48,000 and $183,000, respectively, to
reflect the disposal of property, plant and equipment.
Depreciation expense for the six months ended 30 June 2017 and
2016, and the year ended 31 December 2016 was approximately
$594,000, $708,000 and $1,342,000, respectively, and includes
depreciation on equipment leased to customers. Depreciation expense
on equipment leased to customers included in cost of goods sold for
the six months ended 30 June 2017 and 2016, and the year ended 31
December 2016 was $401,000, $460,000 and $885,000,
respectively.
6. Intangible assets
During 2009, the Company entered into a patent rights purchase
agreement with a shareholder. The agreement provided for the
immediate payment of $28,000 in 2009 with the possibility of an
additional $72,000 based on profits on the sales of a particular
product. During 2010, the Company paid $22,000 based on profits on
the sales of the product and paid the remaining $50,000 in 2011.
The patent is amortised utilising the straight-line method over a
useful life of 17 years which represents the legal life of the
patent from inception. Accumulated amortisation on the patent was
approximately $42,000, $36,000 and $39,000 as of 30 June 2017 and
2016, and 31 December 2016, respectively.
In addition to the purchased patent, the Company has internally
developed patents. Internally developed patents include legal and
registration costs incurred to obtain the respective patents. The
Company currently holds various patents and numerous pending patent
applications in the United States, as well as numerous foreign
jurisdictions outside of the United States.
Intangible assets as of 30 June 2017 and 2016, and 31 December
2016 consist of the following:
Weighted 30 June 30 June 31 December
Average 2017 2016 2016
Useful US$000 US$000 US$000
lives
Internally developed
patents 15 years 1,255 1,177 1,240
Purchased patents 17 years 100 100 100
1,355 1,277 1,340
Less accumulated
amortisation (511) (466) (488)
---------- ---------- --------------
Intangible assets
- net 844 811 852
========== ========== ==============
Approximate aggregate future amortisation expense is as
follows:
Year ending 31 December
(USD, in thousands)
2017 23
2018 46
2019 42
2020 41
2021 41
Thereafter 223
Amortisation expense for the six months ended 30 June 2017 and
2016, and the year ended 31 December 2016 was approximately
$23,000, $20,000 and $42,000, respectively.
7. Income taxes
The components of income taxes shown in the consolidated
statements of operations are as follows:
30 June 30 June 31 December
2017 2016 2016
US$000 US$000 US$000
---------- ---------- --------------
Current:
Federal - - -
Foreign 152 116 197
State - - 2
---------- ---------- --------------
Total current provision 152 116 199
---------- ---------- --------------
Deferred:
Federal - - -
Foreign - - -
State - - -
---------- ---------- --------------
Total deferred provision - - -
---------- ---------- --------------
Total provision for income
taxes 152 116 199
========== ========== ==============
The provision for income tax varies from the amount computed by
applying the statutory corporate federal tax rate of 34 percent,
primarily due to the effect of certain nondeductible expenses,
foreign withholding tax, and changes in valuation allowances.
A reconciliation of the differences between the effective tax
rate and the federal statutory tax rate is as follows:
30 June 30 June 31 December
2017 2016 2016
---------- ---------- --------------
Federal statutory income
tax rate 34.0% 34.0% 34.0%
State tax rate, net of federal
benefit (0.4%) 0.7% (0.1%)
Valuation allowance (47.9%) (37.5%) (36.2%)
Other (0.4%) (0.1%) 0.1%
Foreign withholding tax (28.5%) (5.5%) (4.2%)
---------- ---------- --------------
Effective income tax rate (43.2%) (8.4%) (6.4%)
========== ========== ==============
The significant components of deferred income taxes included in
the balance sheets are as follows:
30 June 30 June 31 December
2017 2016 2016
US$000 US$000 US$000
----------- ---------- --------------
Deferred tax assets
Net operating loss 7,289 6,586 7,140
Equity compensation 424 424 413
Research and development
credits 159 159 159
Allowance for bad debts 72 - 49
Accrued liability 4 8 7
Charitable contributions 10 9 10
Other 37 24 37
Total gross deferred tax
asset 7,995 7,210 7,815
Deferred tax liabilities
Property and equipment (982) (962) (971)
Total gross deferred tax
liability (982) (962) (971)
Net deferred tax asset before
valuation allowance 7,013 6,248 6,844
Valuation allowance (7,013) (6,248) (6,844)
----------- ---------- --------------
Net deferred tax asset (liability) - - -
=========== ========== ==============
Deferred tax assets and liabilities are recorded based on the
difference between an asset or liability's financial statement
value and its tax reporting value using enacted rates in effect for
the year in which the differences are expected to reverse, and for
other temporary differences as defined by ASC-740, Income Taxes. At
30 June 2017, the Company has recorded a valuation allowance of
$7.0 million for which it is more likely than not that the Company
will not receive future tax benefits due to the uncertainty
regarding the realisation of such deferred tax assets.
As of 30 June 2017, the Company has approximately $20.4 million
of gross U.S. federal net operating loss carry forwards and $5.3
million of gross state net operating loss carry forwards that will
begin to expire in the 2019 tax year.
The FASB issued Interpretation ASC-740-10-25, Income Taxes, an
interpretation of ASC-740 which clarifies the accounting for income
taxes by prescribing the minimum recognition threshold a tax
position is required to meet before being recognised in the
financial statements. Under ASC-740, the impact of an uncertain
income tax position on the income tax return must be recognised at
the largest amount that is more likely than not to be sustained
upon audit by the relevant taxing authority. ASC-740 also provides
guidance on derecognition, measurement, classification, interest
and penalties, accounting in interim periods, disclosure and
transition. ASC-740 applies to all tax positions related to income
taxes.
As a result of the adoption and implementation of ASC-740, a tax
position is recognised as a benefit only if it is "more likely than
not" that the tax position would be sustained in a tax examination,
with a tax examination being presumed to occur. The amount
recognised is the largest amount of tax benefit that has a greater
than 50 percent likelihood of being realised on examination. For
tax positions not meeting the "more likely than not" test, no tax
benefit is recorded. The Company recognises interest and penalties
related to tax positions in income tax expense. At 30 June 2017 and
2016, and 31 December 2016, there was no accrual for uncertain tax
positions or related interest.
The Company's tax years 2013 through 2016 remain subject to
examination by federal, state and foreign income tax
jurisdictions.
8. Line of credit
In October 2014, the Company entered into a bank line of credit
that allows for borrowings up to $500,000. The line of credit is
revolving and is payable on demand. There was no balance on the
line of credit at 30 June 2017 and 2016, and 31 December 2016. The
facility matures in October 2017 and is secured by the assignment
of a deposit account held by the lender. The line of credit carries
a variable interest rate of 0.5 percentage points under an
independent index which is the Wall Street Journal Prime and is
calculated by applying the ratio of the interest rate over a year
of 360 days multiplied by the outstanding principal balance
multiplied by the actual number of days the principal balance is
outstanding. The interest rate on 30 June 2017 and 2016, and 31
December 2016 was 3.75 percent, 3.00 percent and 3.25 percent,
respectively. There was no interest expense related to this loan
for the six months ended 30 June 2017 and 2016, and the year ended
31 December 2016.
9. Note payable
On 27 March 2013, the Company entered into a term loan agreement
with a lender for the purchase of property and a building for its
manufacturing operations and corporate offices. The note is secured
by the property and building. The Company borrowed proceeds of
$2,285,908 at a fixed interest rate of 4.45 percent. The loan has a
ten year term with monthly payments based on a twenty year
amortisation. There is a one-time payment at the end of the term of
the note of approximately $1,400,000. In accordance with the terms
of the agreement, the Company is required to keep $500,000 in a
deposit account with the lending bank. As of 30 June 2017 and 2016,
and 31 December 2016, the Company had restricted cash of $500,000
related to the loan agreement. Future maturities of long-term debt
are as follows as of 30 June 2017:
Year ending 31 December
(USD, in thousands)
2017 43
2018 89
2019 93
2020 97
2021 102
Thereafter 1,540
-----
1,964
10. Stock compensation
Stock options
In July 2011, the Company's shareholders approved the Conversion
Shares and the Directors' Shares, as well as the Plan Shares and
Omnibus Performance Incentive Plan ("Plan"). This included the
termination of all outstanding stock incentive plans, cancellation
of all outstanding stock incentive agreements, and the awarding of
stock incentives to Directors and certain employees and
consultants. The Company established the Plan to attract and retain
Directors, officers, employees and consultants. The Company
reserved an amount equal to 10 percent of the Common Shares issued
and outstanding immediately following the Public Offering.
Upon the issuance of these additional shares, an award of share
options was made to the Directors and certain employees and
consultants, and a single award of restricted shares was made to a
former Chief Financial Officer. In addition, additional stock
options were awarded in each year subsequent. The awards of stock
options and restricted shares made upon issuance were in respect of
85 percent of the Common Shares available under the Plan,
equivalent to 8.5 percent of the Public Offering. The total number
of shares reserved for stock awards and options under this Plan is
1,877,011 with 1,192,042 shares allocated as of 30 June 2017. The
shares are all allocated to employees, executives and
consultants.
The options granted to Non-Executive Directors, unless otherwise
agreed, vest contingent on continuing service with the Company at
the vesting date and compliance with the covenants applicable to
such service.
Employee options either vest over three years with a third
vesting ratably each year, or partially on issuance and partially
over the following 24 month period. Vesting accelerates in the
event of a change of control. Options granted to Non-Executive
Directors and one executive vest partially on issuance and will
vest partially one to two years later. The remaining Non-Executive
Director options expired at the end of 2016.
As discussed in Note 2, the Company uses the Black Scholes
valuation model to measure the fair value of options granted. Since
the Company does not have a sufficient trading history from which
to calculate its historical volatility, the Company's expected
volatility is based on a basket of comparable companies' historical
volatility. As the Company's initial options were granted in 2011,
the Company does not have sufficient history of option exercise
behavior from which to calculate the expected term. Accordingly,
the expected terms of options are calculated based on the short-cut
method commonly utilised by newly public companies. The risk free
interest rate is based on a blended average yield of two and five
year United States Treasury Bills at the time of grant. The
assumptions used in the Black Scholes option pricing model for
options granted in 2016 and 2017 were as follows:
Fair
Number Risk-Free Value
of Options Grant Interest Expected Exercise Per
Granted Date Rate Term Volatility Price Option
-------- -------------- ------------- ------------ ----------- ------------- ----------- ----------
5.75
2016 25,000 01/02/2016 1.62% years 56.00% $0.34 $0.18
5.75
345,000 14/03/2016 1.70% years 54.50% $0.40 $0.20
5.75
2017 205,000 26/05/2017 1.69% years 56.70% $0.75 $0.39
The Company assumes a dividend yield of 0.0%.
The following table summarises the Company's stock option
activity for the six months ended 30 June 2017:
Weighted-Average
Weighted-Average Remaining Average Grant
Exercise Contractual Date Fair
Stock Options Shares Price Term (in years) Value
--------------------- ------------ ------------------- ------------------- ----------------
Outstanding at
31 December 2016 1,139,556 $2.56 5.9 $1,372,852
Granted 205,000 $0.75 5.8 $79,950
Forfeited (152,514) $2.04
--------------------- ------------
Outstanding at
30 June 2017 1,192,042 $2.31 5.9 $1,300,481
--------------------- ------------
Exercisable at
30 June 2017 769,292 $3.15 6.4
--------------------- ------------
A summary of the status of unvested options as of 30 June 2017
and changes during the six months ended 30 June 2017 is presented
below:
Weighted-Average
Fair Value
Unvested Options Shares at Grant Date
--------------------------- ----------- -------------------
Unvested at 31 December
2016 341,833 $0.65
Granted 205,000 $0.39
Vested (54,000) $1.16
Forfeited (70,083)
--------------------------- -----------
Unvested at 30 June
2017 422,750 $0.41
--------------------------- -----------
As of 30 June 2017, total unrecognised compensation cost of
$151,000 was related to unvested share-based compensation
arrangements awarded under the Plan.
11. Commitments and contingencies
Operating leases - The Company leases certain facilities and
equipment under non-cancelable operating leases which expire at
varying times between January 2018 and May 2019. Certain of these
leases have escalating rent payments which result in the Company
recording a deferred rent liability.
Future minimum lease payments under the operating leases,
together with the present value of minimum lease payments as of 30
June 2017 are as follows:
Future
Lease
Payments
US$000
Year Ending 31 December
2017 99
2018 116
2019 45
Total future lease payments 260
=========
Rent expense for the six months ended 30 June 2017 and 2016, and
the year ended 31 December 2016 was approximately $165,000,
$172,000 and $337,000, respectively.
12. Related party transactions
The Company has held a patent rights purchase agreement since
2009 with a shareholder as described in Note 6.
13. Segment and geographic information
ASC 280-10, Disclosures About Segments of an Enterprise and
Related Information (ASC 280-10), establishes standards for
reporting information about operating segments. ASC 280-10 requires
that the Company report financial and descriptive information about
its reportable operating segments. Operating segments are
components of an enterprise for which separate financial
information is available that is evaluated regularly by the chief
operating decision maker (CODM) in deciding how to allocate
resources and in assessing performance. The Company's CODM is the
Chief Executive Officer (CEO). While the CEO is apprised of a
variety of financial metrics and information, the business is
principally managed on an aggregate basis as of 30 June 2017. For
the six months ended 30 June 2017, the Company's revenues were
generated primarily in the Middle East and the United States
(U.S.). Additionally, the majority of the Company's expenditures
and personnel either directly supported its efforts in the Middle
East and the U.S., or cannot be specifically attributed to a
geography. Therefore, the Company has only one reportable operating
segment.
Revenues from customers by geography are as follows:
Six months Six months Year ended
ended 30 ended 30 31 December
June June 2016
(USD, in thousands) 2017 2016
Middle East 2,767 2,609 3,989
United States 816 811 1,766
Other 2,294 525 2,168
------------- ------------- ---------------
Total 5,877 3,945 7,923
============= ============= ===============
Equipment leased to customers by geography is as follows:
Six months Six months Year ended
ended 30 ended 30 31 December
June June 2016
(USD, in thousands) 2017 2016
Middle East 6,391 6,391 6,391
United States 1,698 2,118 2,071
Other 375 375 375
------------- ------------- ---------------
Total 8,464 8,884 8,837
============= ============= ===============
14. Concentrations
At 30 June 2017, two customers, one with four contracts with
three separate plants represented 84 percent of accounts
receivable. During the six months ended 30 June 2017, the Company
received 81 percent of its gross revenue from two customers, one
with four contracts with three separate plants.
At 30 June 2016, two customers, one with three contracts with
three separate plants represented 78 percent of accounts
receivable. During the six months ended 30 June 2016, the Company
received 62 percent of its gross revenue from one customer with
three contracts with three separate plants.
At 31 December 2016, two customers, one with three contracts
with three separate plants, represented 61 percent of accounts
receivable. During the year ended 31 December 2016, the Company
received 67 percent of its gross revenue from two customers, one
with three separate plants.
15. Subsequent events
The Company discloses material events that occur after the
balance sheet date but before the financials are issued. In
general, these events are recognised in the financial statements if
the conditions existed at the date of the balance sheet, but are
not recognised if the conditions did not exist at the balance sheet
date. Management has evaluated subsequent events through 13
September 2017, the date the interim results were available to be
issued, and no events have occurred which require further
disclosure.
Forward Looking Statements
This release contains certain statements that are or may be
"forward-looking statements". These statements typically contain
words such as "intends", "expects", "anticipates", "estimates" and
words of similar importance. All the statements other than
statements of historical facts included in this announcement,
including, without limitation, those regarding the Company's
financial position, business strategy, plans and objectives of
management for future operations (including development plans and
objectives relating to the Company's products and services) are
forward-looking statements. By their nature, forward-looking
statements involve risk and uncertainty because they relate to
events and depend on circumstances that will occur in the future
and therefore undue reliance should not be placed on such
forward-looking statements. There are a number of factors that
could cause the actual results, performance or achievements of the
Company to be materially different from future results, performance
or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous
assumptions regarding the Company's present and future business
strategies and the environment in which the Company will operate in
the future and such assumptions may or may not prove to be correct.
Forward-looking statements speak only as at the date they are made.
Neither the Company nor any other person undertakes any obligation
(other than, in the case of the Company, pursuant to the AIM Rules
for Companies) to update publicly any of the information contained
in this announcement, including any forward-looking statements, in
the light of new information, change in circumstances or future
events.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR KLLFFDKFZBBB
(END) Dow Jones Newswires
September 13, 2017 02:01 ET (06:01 GMT)
Mycelx Technologies (LSE:MYXR)
Historical Stock Chart
From May 2024 to Jun 2024
Mycelx Technologies (LSE:MYXR)
Historical Stock Chart
From Jun 2023 to Jun 2024